BAUDETTE, Minn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Leerink Partners Global Biopharma Conference in Miami Beach as follows: Date: Tuesday, March 12, 2024   Time: 2:20 p.m. ET   Webcast: Click Here    To schedule a 1x1 meeting with the Company, please contact your Leerink representative. The live and archived webcast will be ...

The latest trading session saw ANI Pharmaceuticals (ANIP) ending at $57.03, denoting a +0.92% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily loss of 0.1%. Elsewhere, the Dow gained 0.33%, while the tech-heavy Nasdaq lost 0.3%.Prior to today's trading, shares of the drugmaker had lost 0.41% over the past month. This has lagged the Medical sector's gain of 2.32% and the S&P 500's gain of 5.78% in that time.The investment community will be closely monitoring the ...

BAUDETTE, Minn., Feb. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, February 29, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date Thursday, February 29, 2024    ...

The most recent trading session ended with ANI Pharmaceuticals (ANIP) standing at $56.04, reflecting a +1.12% shift from the previouse trading day's closing. The stock's change was more than the S&P 500's daily loss of 0.32%. On the other hand, the Dow registered a loss of 0.71%, and the technology-centric Nasdaq decreased by 0.2%.Heading into today, shares of the drugmaker had lost 2.38% over the past month, lagging the Medical sector's gain of 2.33% and the S&P 500's gain of 4.59% in that time.Investors w ...

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $55.02, marking a +0.7% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.76%. Meanwhile, the Dow experienced a rise of 0.59%, and the technology-dominated Nasdaq saw an increase of 1.12%.Prior to today's trading, shares of the drugmaker had lost 0.91% over the past month. This has lagged the Medical sector's gain of 1.57% and the S&P 500's gain of 2.5% in that time.The investment community will be ...

BAUDETTE, Minn., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York City as follows: Date: Thursday, February 8, 2024   Time: 10:30 a.m. ET   Webcast:  Click Here     To schedule a 1x1 meeting with the Company, please email: gsmanagementaccess@guggenheimpartners.com The live and archi ...

Core Viewpoint - ANI Pharmaceuticals, Inc. has launched Pentoxifylline Extended-Release (ER) Tablets, a generic version of Trental®, targeting a U.S. market valued at approximately $19.7 million annually [1][2]. Company Overview - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription products, particularly for diseases with high unmet medical needs [3]. - The company aims to achieve sustainable growth by expanding its Rare Disease business and enhancing its generics business through improved research and development capabilities [3]. Product Launch - The launch of Pentoxifylline ER Tablets is part of ANI's strategy to continue momentum in its generics business within a limited competition market [2]. - The company emphasizes a patient-first approach, ensuring access to high-quality therapeutics for patients and healthcare providers [2].

The most recent trading session ended with ANI Pharmaceuticals (ANIP) standing at $56.17, reflecting a +1.37% shift from the previouse trading day's closing. This change outpaced the S&P 500's 0.22% gain on the day. At the same time, the Dow added 0.36%, and the tech-heavy Nasdaq gained 0.32%.The drugmaker's stock has climbed by 3.71% in the past month, exceeding the Medical sector's gain of 2.3% and the S&P 500's gain of 1.61%.Analysts and investors alike will be keeping a close eye on the performance of A ...

ANI Pharmaceuticals (ANIP) closed the most recent trading day at $55.41, moving -0.32% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.23%. On the other hand, the Dow registered a gain of 1.06%, and the technology-centric Nasdaq increased by 1.7%.Coming into today, shares of the drugmaker had gained 4.63% in the past month. In that same time, the Medical sector gained 3.16%, while the S&P 500 gained 0.94%.The investment community will be closely monitoring ...

BAUDETTE, Minn., Jan. 16, 2024 (GLOBE NEWSWIRE) --  ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Indomethacin Oral Suspension (OS), USP. ANI's Indomethacin OS is the generic version of the Reference Listed Drug (RLD) Indocin® Oral Suspension. The current annual U.S. market for Indomethacin OS is approximately $4.1 million, according to the latest estimates fro ...